Cash-rich Novartis CEO mulls biotech buyouts
With $8 billion burning a hole in its pocket after the sale of two big divisions, Novartis CEO Daniel Vasella says that the company may spend part of that money on new biotech acquisitions. In an interview with Finanz und Wirtschaft, Vasella was distinctly silent on rumors that the company was interested in acquiring MedImmune, which recently was put on the sales block. Vasella was more forthcoming about his interest in buyouts in biotechnology, vaccines and over-the-counter medicines. Novartis may also use part of its funds to initiate a stock buyback.
- read the AFX report on Novartis' plans
Related Articles:
Novartis makes a $10B bet on generic drugs. Report
EMEA committee rejects Novartis' Zelnorm. Report
Novartis sells Gerber for $5.5B to Nestlé. Release
Be the first to comment
Comments
Post new comment
Paid Research Reports
- Leading Drug Delivery Companies and Technologies: Competitive landscape, company profiles and technological developments
- Drug Repositioning Strategies - Serendipity by design
- eHealthInsight Series: Online Patient Recruitment Strategies - Optimizing the clinical trial process
- Pricing & Reimbursement - Seven Major Markets Update
- Innovative Clinical Trial Design and Management: Trends, success stories and impact upon R&D budgets
